Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range

Journal of Bone and Mineral Research

Volumn 30, Issue 7, 2015, Pages 1119-1133

  El Hajj Fuleihan, Ghada ^a   Bouillon, Roger ^b   Clarke, Bart ^c   Chakhtoura, Marlene ^a   Cooper, Cyrus ^d   McClung, Michael ^e   Singh, Ravinder J ^c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

DESIRABLE RANGE; EFFICACY; ETHNICITIES; KNOWLEDGE GAPS; SAFETY; VARIATIONS; VITAMIN D

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D; 25-HYDROXYVITAMIN D;

ACCURACY; ATTITUDE TO HEALTH; BONE DENSITY; BONE MINERAL; CONCEPTUAL FRAMEWORK; DIETARY INTAKE; DRUG SAFETY; ENVIRONMENTAL FACTOR; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GROUPS BY AGE; HEREDITY; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; LIFESTYLE; META ANALYSIS (TOPIC); OSTEOPOROSIS; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SEASONAL VARIATION; STANDARDIZATION; SYSTEMATIC REVIEW (TOPIC); VITAMIN BLOOD LEVEL; VITAMIN D INTOXICATION; VITAMIN D METABOLISM; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; ADVERSE EFFECTS; AGE DISTRIBUTION; ANALOGS AND DERIVATIVES; BIOASSAY; BLOOD; DIETARY SUPPLEMENT; KNOWLEDGE; REFERENCE VALUE;

AGE DISTRIBUTION; BIOLOGICAL ASSAY; DIETARY SUPPLEMENTS; HUMANS; KNOWLEDGE; REFERENCE VALUES; VITAMIN D;

EID: 84931957121     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2536     Document Type: Review

References (157)

1. Holick MF,. Vitamin D deficiency. N Engl J Med. 2007; 357 (3): 266-81.
2. Bouillon R, Carmeliet G, Verlinden L, et al., Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008; 29 (6): 726-76.
3. Bouillon R, Van Schoor NM, Gielen E, et al., Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J Clin Endocr Metab. 2013; 98 (8): E1283-304.
4. Rosen CJ,. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011; 364 (3): 248-54.
5. Lips P, van Schoor NM,. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab. 2011; 25 (4): 585-91.
6. Lips P., Worldwide status of vitamin D nutrition. J Steroid Biochem Mol Biol. 2010; 121 (1-2): 297-300.
7. Mithal A, Wahl DA, Bonjour JP, et al., Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009; 20 (11): 1807-20.
8. Wahl DA, Cooper C, Ebeling PR, et al., A global representation of vitamin D status in healthy populations. Arch Osteoporos. 2012; 7 (1-2): 155-72.
9. Looker AC, Johnson CL, Lacher DA, Pfeiffer CM, Schleicher RL, Sempos CT,. Vitamin D status: United States, 2001-2006. NCHS Data Brief. 2011 (59): 1-8.
10. El-Hajj Fuleihan G, Rahme M, Bassil D., Do desirable vitamin D levels vary globally? In:, Burckhardt P, Dawson-Hughes B, Weaver C, editors. Nutritional Influences on Bone Health: 8th International Symposium. London: Springer Verlag 2013. p. 273-300.
11. Hilger J, Friedel A, Herr R, et al., A systematic review of vitamin D status in populations worldwide. Br J Nutr. 2014; 111 (1): 23-45.
12. Lips P, Gielen E, van Schoor NM,. Vitamin D supplements with or without calcium to prevent fractures. Bonekey Rep. 2014; 3: 512.
13. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP,. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ. 2014; 348: g2035.
14. Avenell A, Mak JC, O'Connell D., Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev. 2014; 4: CD000227.
15. Moyer VA,. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013; 158 (9): 691-6.
16. Institute of Medicine (IOM). Dietary reference intake for calcium and vitamin D. Washington DC: National Academies Press; 2011 [cited 2015 Apr 27]. Available from: http://www.nal.usda.gov/fnic/DRI/DRI-Calcium-Vitamin-D/FullReport.pdf.
17. Ross AC, Manson JE, Abrams SA, et al., The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011; 96 (1): 53-8.
18. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al., Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. The J Clin Endocrinol Metab. 2011; 96 (7): 1911-30.
19. Watts NB, Bilezikian JP, Camacho PM, et al., American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010; 16 Suppl 3: 1-37.
20. Bassil D, Rahme M, Hoteit M, Fuleihan Gel H., Hypovitaminosis D in the Middle East and North Africa: Prevalence, risk factors and impact on outcomes. Dermatoendocrinol. 2013; 5 (2): 274-98.
21. Van Schoor NM, Lips P., Worldwide vitamin D status. Best Pract Res Clin Endocrinol Metab. 2011; 25 (4): 671-80.
22. Winzenberg T, Jones G., Vitamin D and bone health in childhood and adolescence. Calcif Tissue Int. 2013; 92 (2): 140-50.
23. Moon RJ, Harvey NC, Davies JH, Cooper C., Vitamin D and skeletal health in infancy and childhood. Osteoporos Int. 2014; 25 (12): 2673-84.
24. Harvey NC, Holroyd C, Ntani G, et al., Vitamin D supplementation in pregnancy: a systematic review. Health Technol Assess. 2014; 18 (45): 1-190.
25. Rosen CJ, Abrams SA, Aloia JF, et al., IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrinol Metab. 2012; 97 (4): 1146-52.
26. Rosen CJ, Taylor CL,. Common misconceptions about vitamin D-implications for clinicians. Nat Rev Endocrinol. 2013; 9 (7): 434-8.
27. Heaney RP, Holick MF,. Why the IOM recommendations for vitamin D are deficient. J Bone Miner Res. 2011; 26 (3): 455-7.
28. Heaney RP,. Vitamin D-baseline status and effective dose. N Engl J Med. 2012; 367 (1): 77-8.
29. Vogiatzi MG, Jacobson-Dickman E, DeBoer MD,. Vitamin D supplementation and risk of toxicity in pediatrics: a review of current literature. J Clin Endocrinol Metab. 2014; 99 (4): 1132-41.
30. Awada Z, Ossaily S, Zgheib NK,. The nutrigenetics and pharmacogenetics of vitamin D pathways. Curr Pharmacogenomics Person Med. 2014; 12 (2): 89-103.
31. Hunter D, De Lange M, Snieder H, et al., Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J Bone Miner Res. 2001; 16 (2): 371-8.
32. Orton SM, Morris AP, Herrera BM, et al., Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr. 2008; 88 (2): 441-7.
33. Karohl C, Su S, Kumari M, et al., Heritability and seasonal variability of vitamin D concentrations in male twins. Am J Clin Nutr. 2010; 92 (6): 1393-8.
34. Wang TJ, Zhang F, Richards JB, et al., Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 2010; 376 (9736): 180-8.
35. Ahn J, Yu K, Stolzenberg-Solomon R, et al., Genome-wide association study of circulating vitamin D levels. Hum Mol Genet. 2010; 19 (13): 2739-45.
36. Arabi A, Mahfoud Z, Zahed L, El-Onsi L, El-Hajj Fuleihan G., Effect of age, gender and calciotropic hormones on the relationship between vitamin D receptor gene polymorphisms and bone mineral density. Eur J Clin Nutr. 2010; 64 (4): 383-91.
37. Waterhouse M, Tran B, Armstrong BK, et al., Environmental, personal, and genetic determinants of response to vitamin D supplementation in older adults. J Clin Endocrinol Metab. 2014; 99 (7): E1332-40.
38. Nowson CA, McGrath JJ, Ebeling PR, et al., Vitamin D and health in adults in Australia and New Zealand: a position statement. Med J Aust. 2012; 196 (11): 686-7.
39. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al., Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009; 339: b3692.
40. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B., Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005; 293 (18): 2257-64.
41. Nassar N, Halligan GH, Roberts CL, Morris JM, Ashton AW,. Systematic review of first-trimester vitamin D normative levels and outcomes of pregnancy. Am J Obstet Gynecol. 2011; 205 (3): 208e1-7.
42. Bodnar LM, Catov JM, Zmuda JM, et al., Maternal serum 25-hydroxyvitamin D concentrations are associated with small-for-gestational age births in white women. J Nutr. 2010; 140 (5): 999-1006.
43. Bodnar LM, Catov JM, Simhan HN, Holick MF, Powers RW, Roberts JM,. Maternal vitamin D deficiency increases the risk of preeclampsia. J Clin Endocrinol Metab. 2007; 92 (9): 3517-22.
44. Merewood A, Mehta SD, Chen TC, Bauchner H, Holick MF,. Association between vitamin D deficiency and primary cesarean section. J Clin Endocrinol Metab. 2009; 94 (3): 940-5.
45. Powe CE, Seely EW, Rana S, et al., First trimester vitamin D, vitamin D binding protein, and subsequent preeclampsia. Hypertension. 2010; 56 (4): 758-63.
46. Wei SQ, Audibert F, Hidiroglou N, et al., Longitudinal vitamin D status in pregnancy and the risk of pre-eclampsia. B J Obstet Gyn. 2012; 119 (7): 832-9.
47. Leffelaar ER, Vrijkotte TG, van Eijsden M., Maternal early pregnancy vitamin D status in relation to fetal and neonatal growth: results of the multi-ethnic Amsterdam Born Children and their Development cohort. Br J Nutr. 2010; 104 (1): 108-17.
48. Morley R, Carlin JB, Pasco JA, Wark JD,. Maternal 25-hydroxyvitamin D and parathyroid hormone concentrations and offspring birth size. J Clin Endocrinol Metab. 2006; 91 (3): 906-12.
49. Bodnar LM, Platt RW, Simhan HN,. Early-pregnancy vitamin D deficiency and risk of preterm birth subtypes. Obstet Gynecol. 2015; 125 (2): 439-47.
50. Aghajafari F, Nagulesapillai T, Ronksley PE, Tough SC, O'Beirne M, Rabi DM,. Association between maternal serum 25-hydroxyvitamin D level and pregnancy and neonatal outcomes: systematic review and meta-analysis of observational studies. BMJ. 2013; 346: f1169.
51. Poel YH, Hummel P, Lips P, Stam F, van der Ploeg T, Simsek S., Vitamin D and gestational diabetes: a systematic review and meta-analysis. Eur J Intern Med. 2012; 23 (5): 465-9.
52. Wei SQ, Qi HP, Luo ZC, Fraser WD,. Maternal vitamin D status and adverse pregnancy outcomes: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2013; 26 (9): 889-99.
53. Tabesh M, Salehi-Abargouei A, Esmaillzadeh A., Maternal vitamin D status and risk of pre-eclampsia: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013; 98 (8): 3165-73.
54. Thorne-Lyman A, Fawzi WW,. Vitamin D during pregnancy and maternal, neonatal and infant health outcomes: a systematic review and meta-analysis. Paediatr Perinat Epidemiol. 2012; 26 Suppl 1: 75-90.
55. De-Regil LM, Palacios C, Ansary A, Kulier R, Pena-Rosas JP,. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev. 2012; 2: CD008873.
56. Galthen-Sørensen M, Andersen LB, Sperling L, Christesen HT,. Maternal 25-hydroxyvitamin D level and fetal growth assessed by ultrasound: a systematic review. Ultrasound Obstet Gynecol. 2014 Dec; 44 (6): 633-40.
57. Javaid MK, Crozier SR, Harvey NC, et al., Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet. 2006; 367 (9504): 36-43.
58. Zhu K, Whitehouse AJ, Hart PH, et al., Maternal vitamin D status during pregnancy and bone mass in offspring at 20 years of age: a prospective cohort study. J Bone Miner Res. 2014; 29 (5): 1088-95.
59. Hart PH, Lucas RM, Walsh JP, et al., Vitamin D in fetal development: findings from a birth cohort study. Pediatrics. 2015; 135 (1): e167-73.
60. Harvey NC, Moon RJ, Sayer AA, et al., Maternal antenatal vitamin D status and offspring muscle development: findings from the Southampton Women's Survey. J Clin Endocrinol Metab. 2014; 99 (1): 330-7.
61. Lawlor DA, Wills AK, Fraser A, Sayers A, Fraser WD, Tobias JH,. Association of maternal vitamin D status during pregnancy with bone-mineral content in offspring: a prospective cohort study. Lancet. 2013; 381 (9884): 2176-83.
62. Sayers A, Tobias JH,. Estimated maternal ultraviolet B exposure levels in pregnancy influence skeletal development of the child. J Clin Endocrinol Metab. 2009; 94 (3): 765-71.
63. World Health Organization (WHO), Guideline: Vitamin D supplementation in pregnant women 2012. Geneva: World Health Organization; 2012 [cited 2015 Apr 27]. Available from: http://apps.who.int/iris/bitstream/10665/85313/1/9789241504935-eng.pdf.
64. Karras SN, Anagnostis P, Bili E, et al., Maternal vitamin D status in pregnancy and offspring bone development: the unmet needs of vitamin D era. Osteoporos Int. 2014; 25 (3): 795-805.
65. Winzenberg T, Powell S, Shaw KA, Jones G., Effects of vitamin D supplementation on bone density in healthy children: systematic review and meta-analysis. BMJ. 2011; 342: c7254.
66. El-Hajj Fuleihan G, Nabulsi M, Tamim H, et al., Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab. 2006; 91 (2): 405-12.
67. Lehtonen-Veromaa MK, Mottonen TT, Nuotio IO, Irjala KM, Leino AE, Viikari JS,. Vitamin D and attainment of peak bone mass among peripubertal Finnish girls: a 3-y prospective study. Am J Clin Nutr. 2002; 76 (6): 1446-53.
68. Kumar GT, Sachdev HS, Chellani H, et al., Effect of weekly vitamin D supplements on mortality, morbidity, and growth of low birthweight term infants in India up to age 6 months: randomised controlled trial. BMJ. 2011; 342: d2975.
69. Khadilkar AV, Sayyad MG, Sanwalka NJ, et al., Vitamin D supplementation and bone mass accrual in underprivileged adolescent Indian girls. Asia Pac J Clin Nutr. 2010; 19 (4): 465-72.
70. International Osteoporosis Foundation. Asian Audit [Internet]. Nyon, Switzerland: International Osteoporosis Foundation; 2009 [cited 2015 Apr 27]. Available from: http://www.iofbonehealth.org/asian-audit.
71. International Osteoporosis Foundation. Middle East Africa Audit [Internet]. Nyon, Switzerland: International Osteoporosis Foundation; 2011 [cited 2015 Apr 27]. Available from: http://www.iofbonehealth.org/middle-east-africa-audit.
72. Cauley JA, Danielson ME, Boudreau R, et al., Serum 25-hydroxyvitamin D and clinical fracture risk in a multiethnic cohort of women: the Women's Health Initiative (WHI). J Bone Miner Res. 2011; 26 (10): 2378-88.
73. Holick MF,. The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. Mol Aspects Med. 2008; 29 (6): 361-8.
74. Makariou S, Liberopoulos EN, Elisaf M, Challa A., Novel roles of vitamin D in disease: what is new in 2011? Eur J Intern Med. 2011; 22 (4): 355-62.
75. Sempos CT, Durazo-Arvizu RA, Dawson-Hughes B, et al., Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the U.S. nationally representative NHANES. J Clin Endocrinol Metab. 2013; 98 (7): 3001-9.
76. Bjelakovic G, Gluud LL, Nikolova D, et al., Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2014; 1: CD007470.
77. Pludowski P, Holick MF, Pilz S, et al., Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev. 2013; 12 (10): 976-89.
78. Seida JC, Mitri J, Colmers IN, et al., Effect of vitamin d3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014; 99 (10): 3551-60.
79. Pathak K, Soares MJ, Calton EK, Zhao Y, Hallett J., Vitamin D supplementation and body weight status: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2014; 15 (6): 528-37.
80. Maalmi H, Ordonez-Mena JM, Schottker B, Brenner H., Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. Eur J Cancer. 2014; 50 (8): 1510-21.
81. Li M, Chen P, Li J, Chu R, Xie D, Wang H., Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014; 99 (7): 2327-36.
82. Ford JA, MacLennan GS, Avenell A, Bolland M, Grey A, Witham M., Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. Am J Clin Nutr. 2014; 100 (3): 746-55.
83. Chowdhury R, Kunutsor S, Vitezova A, et al., Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ. 2014; 348: g1903.
84. Keum N, Giovannucci E., Vitamin D supplements and cancer incidence and mortality: a meta-analysis. Br J Cancer. 2014; 111 (5): 976-80.
85. Kim Y, Je Y., Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer. 2014; 110 (11): 2772-84.
86. Rajabbik MH, Lotfi T, Alkhaled L, et al., Association between low vitamin D levels and the diagnosis of asthma in children: a systematic review of cohort studies. Allergy Asthma Clin Immunol. 2014; 10 (1): 31.
87. Valipour G, Saneei P, Esmaillzadeh A., Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies. J Clin Endocrinol Metab. 2014; 99 (10): 3863-72.
88. LeBlanc ES, Zakher B, Daeges M, Pappas M, Chou R., Screening for vitamin D deficiency: a systematic review for the U.S. Preventive services task force. Ann Intern Med. 2015; 162 (2): 109-22.
89. Autier P, Boniol M, Pizot C, Mullie P., Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2014; 2 (1): 76-89.
90. Watts NB, Harris ST, Genant HK, et al., Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990; 323 (2): 73-9.
91. Liberman UA, Weiss SR, Broll J, et al., Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333 (22): 1437-43.
92. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR,. Design of the Fracture Intervention Trial. Osteoporos Int. 1993; 3 Suppl 3: S29-39.
93. Black DM, Delmas PD, Eastell R, et al., Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356 (18): 1809-22.
94. Black DM, Cummings SR, Karpf DB, et al., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348 (9041): 1535-41.
95. Cummings SR, Black DM, Thompson DE, et al., Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280 (24): 2077-82.
96. Orwoll E, Ettinger M, Weiss S, et al., Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343 (9): 604-10.
97. Orwoll ES, Scheele WH, Paul S, et al., The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18 (1): 9-17.
98. Harris ST, Watts NB, Genant HK, et al., Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282 (14): 1344-52.
99. Reginster J, Minne HW, Sorensen OH, et al., Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11 (1): 83-91.
100. McClung MR, Geusens P, Miller PD, et al., Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344 (5): 333-40.
101. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD,. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2009; 24 (4): 719-25.
102. Delmas PD, Recker RR, Chesnut CH III, et al., Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004; 15 (10): 792-8.
103. Ettinger B, Black DM, Mitlak BH, et al., Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282 (7): 637-45.
104. Neer RM, Arnaud CD, Zanchetta JR, et al., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344 (19): 1434-41.
105. Greenspan SL, Bone HG, Ettinger MP, et al., Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007; 146 (5): 326-39.
106. Lyles KW, Colon-Emeric CS, Magaziner JS, et al., Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357 (18): 1799-809.
107. Orwoll ES, Miller PD, Adachi JD, et al., Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010; 25 (10): 2239-50.
108. Cummings SR, San Martin J, McClung MR, et al., Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361 (8): 756-65.
109. Orwoll E, Teglbjaerg CS, Langdahl BL, et al., A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012; 97 (9): 3161-9.
110. Meunier PJ, Roux C, Seeman E, et al., The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004; 350 (5): 459-68.
111. Reginster JY, Seeman E, De Vernejoul MC, et al., Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005; 90 (5): 2816-22.
112. Kaufman JM, Audran M, Bianchi G, et al., Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab. 2013; 98 (2): 592-601.
113. Silverman SL, Christiansen C, Genant HK, et al., Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008; 23 (12): 1923-34.
114. Cummings SR, Ettinger B, Delmas PD, et al., The effects of tibolone in older postmenopausal women. N Engl J Med. 2008; 359 (7): 697-708.
115. Cummings SR, Ensrud K, Delmas PD, et al., Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010; 362 (8): 686-96.
116. Jones G., Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008; 88 (2): 582S-6S.
117. de Paula FJ, Rosen CJ,. Vitamin D safety and requirements. Arch Biochem Biophys. 2012; 523 (1): 64-72.
118. Dudenkov D, Yawn B, Oberhelman S, et al., Incidence of vitamin D toxicity: a population-based study in Olmsted County, Minnesota. J Bone Miner Res. 2013; 28 Suppl 1: S33. [Presented orally at: Annual Meeting American Society for Bone and Mineral Research (ASBMR); 2013 Oct 4-7; Baltimore, MD, USA; Presentation Number: 1098]. Available from: http://www.asbmr.org/education/AbstractDetail?aid=efb70ce4-adf7-4819-9ae3-652b1260a32d.
119. Maalouf J, Nabulsi M, Vieth R, et al., Short- and long-term safety of weekly high-dose vitamin D3 supplementation in school children. J Clin Endocrinol Metab. 2008; 93 (7): 2693-701.
120. Jacobus CH, Holick MF, Shao Q, et al., Hypervitaminosis D associated with drinking milk. N Engl J Med. 1992; 326 (18): 1173-7.
121. Kara C, Gunindi F, Ustyol A, Aydin M., Vitamin D intoxication due to an erroneously manufactured dietary supplement in seven children. Pediatrics. 2014; 133 (1): e240-4.
122. European Food Safety Authority (EFSA)., EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the Tolerable Upper Intake Level of vitamin D. EFSA J. 2012; 10 (7): 2813. doi: 10.2903/j.efsa.2012.2813. Available from: http://www.efsa.europa.eu/en/search/doc/2813.pdf.
123. Vieth R, Ladak Y, Walfish PG,. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab. 2003; 88 (1): 185-91.
124. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ,. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003; 77 (1): 204-10.
125. Gallagher JC, Sai A, Templin T II, Smith L., Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Ann Intern Med. 2012; 156 (6): 425-37.
126. Gallagher JC, Smith LM, Yalamanchili V., Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women. Menopause. 2014; 21 (11): 73-80.
127. Zhao LJ, Zhou Y, Bu F, et al., Factors predicting vitamin D response variation in non-Hispanic white postmenopausal women. J Clin Endocrinol Metab. 2012; 97 (8): 2699-705.
128. Sanders KM, Stuart AL, Williamson EJ, et al., Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010; 303 (18): 1815-22.
129. Amrein K, Quraishi SA, Litonjua AA, et al., Evidence for a U-shaped relationship between prehospital vitamin D status and mortality: a cohort study. J Clin Endocrinol Metab. 2014; 99 (4): 1461-9.
130. Durup D, Jørgensen HL, Christensen J, Schwarz P, Heegaard AM, Lind B., A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab. 2012; 97 (8): 2644-52.
131. Michaelsson K, Baron JA, Snellman G, et al., Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr. 2010; 92 (4): 841-8.
132. Melamed ML, Michos ED, Post W, Astor B., 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008; 168 (15): 1629-37.
133. Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, Gandini S., Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr. 2012; 95 (1): 91-100.
134. Bleicher K, Cumming RG, Naganathan V, et al., U-shaped association between serum 25-hydroxyvitamin D and fracture risk in older men: results from the prospective population-based CHAMP study. J Bone Miner Res. 2014; 29 (9): 2024-31.
135. Petersen B, Wulf HC, Triguero-Mas M, et al., Sun and ski holidays improve vitamin D status, but are associated with high levels of DNA damage. J Investig Dermatol. 2014; 134 (11): 2806-13.
136. Binkley N, Lewiecki EM,. Vitamin D and common sense. J Clin Densitom. 2011; 14 (2): 95-9.
137. Luxwolda MF, Kuipers RS, Kema IP, Dijck-Brouwer DA, Muskiet FA,. Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l. Br J Nutr. 2012; 108 (9): 1557-61.
138. Durazo-Arvizu RA, Camacho P, Bovet P, et al., 25-Hydroxyvitamin D in African-origin populations at varying latitudes challenges the construct of a physiologic norm. Am J Clin Nutr. 2014; 100 (3): 908-14.
139. Carter GD,. Accuracy of 25-hydroxyvitamin D assays: confronting the issues. Curr Drug Targets. 2011; 12 (1): 19-28.
140. Sempos CT, Vesper HW, Phinney KW, Thienpont LM, Coates PM,. Vitamin D status as an international issue: national surveys and the problem of standardization. Scand J Clin Lab Invest Suppl. 2012; 243: 32-40.
141. Glendenning P, Taranto M, Noble JM, et al., Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Ann Clin Biochem. 2006; 43: 23-30.
142. Carter GD, Carter R, Jones J, Berry J., How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem. 2004; 50 (11): 2195-7.
143. Binkley N, Krueger D, Cowgill CS, et al., Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab. 2004; 89 (7): 3152-7.
144. Barake M, Daher RT, Salti I, et al., 25-hydroxyvitamin D assay variations and impact on clinical decision making. J Clin Endocrinol Metab. 2012; 97 (3): 835-43.
145. DEQAS (Vitamin D External Quality Assessment Scheme) [Internet]. London, UK: DEQAS [cited 2015 Apr 27]. Available from: http://www.deqas.org.
146. Ong L, Saw S, Sahabdeen NB, Tey KT, Ho CS, Sethi SK,. Current 25-hydroxyvitamin D assays: do they pass the test? Clin Chim Acta. 2012; 413 (13-14): 1127-34.
147. Janssen MJ, Wielders JP, Bekker CC, et al., Multicenter comparison study of current methods to measure 25-hydroxyvitamin D in serum. Steroids. 2012; 77 (13): 1366-72.
148. Binkley N, Sempos CT,. Standardizing vitamin D assays: the way forward. J Bone Miner Res. 2014; 29 (8): 1709-14.
149. Osteoporosis Canada. New vitamin D guidelines-Physicians say Canadians should be taking more supplements [Internet]. Toronto, OR; 2015 Jan 14 [cited 2015 Apr 27]. Available from: http://www.osteoporosis.ca/news/press-releases/new-vitamin-d-guidelines.
150. National Osteoporosis Society. Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management [Internet]. Camerton, Bath, UK: National Osteoporosis Society; 2013 [cited 2015 Apr 27]. Available from: http://www.nos.org.uk/document.doc?id=1352.
151. American Association Of Clinical Endocrinologists (AACE). The long awaited Institute of Medicine report on "Dietary Reference Intakes for Calcium and Vitamin D" was released November 30th and is available [Internet]. Jacksonville, FL: American Association Of Clinical Endocrinologists; 2010 [cited 2015 Apr 27]. Available from: https://www.aace.com/article/106.
152. LeFevre ML,. Screening for vitamin d deficiency in adults: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2015; 162 (2): 133-40.
153. International Osteoporosis Foundation. New Vitamin D recommendations for older men and women [Internet]. Nyon, Switzerland: International Osteoporosis Foundation; 2010 [cited 2015 Apr 27]. Available from: http://www.iofbonehealth.org/new-vitamin-d-recommendations-older-men-and-women
154. Al-Shaar L, Mneimneh R, Nabulsi, Maalouf J, El-Hajj Fuleihan G., Vitamin D3 dose requirement to raise 25-hydroxyvitamin D to desirable levels in adolescents: results from a randomized controlled trial. J Bone Miner Res. 2014; 29 (4): 944-51.
155. El-Hajj Fuleihan. Phase III Study on the Effect of Vitamin D Supplementation on Indices of Mineral and Musculoskeletal Metabolism and on Parameters of Glucose and Fuel Metabolism in Elderly Subjects [Internet]. [cited 2015 Apr 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT01315366.
156. Cashman KD, Fitzgerald AP, Kiely M, Seamans KM,. A systematic review and meta-regression analysis of the vitamin D intake-serum 25-hydroxyvitamin D relationship to inform European recommendations. Br J Nutr. 2011; 106 (11): 1638-48.
157. Chakhtoura M, Akl EA, Arabi A, El Ghandour S, Shawwa K, El Hajj Fuleihan G., Effects of different doses of vitamin D replacement in Middle Eastern and North African Population: a systematic review and meta-analysis [Internet]. 2014 [cited 2015 Apr 27]. Available from: http://www.crd.york.ac.uk/PROSPEROFILES/10488-PROTOCOL-20140711.pdf.